UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 119

Sortiert nach

Assessment of pancreatic β-cell function: review of methods and clinical applications

Current diabetes reviews, 2014-01, Vol.10 (1), p.2

2014

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic Manipulation of Myocardial Metabolism

Journal of the American College of Cardiology, 2021-04, Vol.77 (16), p.2022-2039

2021

Link zum Volltext

Verfügbarkeit prüfen

Understanding the kidneys' role in blood glucose regulation

The American journal of managed care, 2012-01, Vol.18 (1 Suppl), p.S11-S16

Triplitt, Curtis L

2012

Link zum Volltext

Verfügbarkeit prüfen

887-P: Renal Benefit of Dapagliflozin Therapy in Hyperfiltering Type 2 Diabetes Patients

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Link zum Volltext

Verfügbarkeit prüfen

124-OR: Effects of Dapagliflozin Therapy on Renal Hemodynamics in Type 2 Diabetes Patients

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Link zum Volltext

Verfügbarkeit prüfen

Examining the mechanisms of glucose regulation

The American journal of managed care, 2012-01, Vol.18 (1 Suppl), p.S4-10

Triplitt, Curtis L

2012

Link zum Volltext

Verfügbarkeit prüfen

Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists

American journal of health-system pharmacy, 2021-03, Vol.78 (7), p.556-567

2021

Link zum Volltext

Verfügbarkeit prüfen

A Special Thanks to Lyn Reynolds, Director of the ADA Editorial Office, as She Embarks on Her Retirement

Diabetes care, 2022-08, Vol.45 (8), p.1707-1708

2022

Link zum Volltext

Verfügbarkeit prüfen

A Special Thanks to Lyn Reynolds, Director of the ADA Editorial Office, as She Embarks on Her Retirement

Diabetes (New York, N.Y.), 2022-08, Vol.71 (8), p.1601-1602

2022

Link zum Volltext

Verfügbarkeit prüfen

857-P: Mechanisms of Dapagliflozin to Reduce Intraglomerular Pressure in Patients with Type 2 Diabetes

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Link zum Volltext

Verfügbarkeit prüfen

Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients

Diabetes, obesity & metabolism, 2017-06, Vol.19 (6), p.809-813

2017

Link zum Volltext

Verfügbarkeit prüfen

99-LB: Myocardial Blood Flow in Association with Baseline Ejection Fraction after Elevation in Plasma Ketones in Patients with T2DM and Heart Failure

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Link zum Volltext

Verfügbarkeit prüfen

Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy

Diabetes (New York, N.Y.), 2018-06, Vol.67 (6), p.1182-1189

2018

Link zum Volltext

Verfügbarkeit prüfen

Oh, What Times We Live In

Diabetes spectrum, 2019-02, Vol.32 (1), p.3-4

Triplitt, Curtis L

2019

Link zum Volltext

Verfügbarkeit prüfen

Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors

Diabetes (New York, N.Y.), 2020-04, Vol.69 (4), p.681-688

2020

Link zum Volltext

Verfügbarkeit prüfen

644-P: Effect of PharmacologIC (EPIC) Therapy on Insulin Sensitivity and Beta-Cell Function in Prediabetes (PreDM)

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Link zum Volltext

Verfügbarkeit prüfen

175-OR: Effect of Hyperketonemia on Cardiac Efficiency in Patients with Heart Failure and Type 2 Diabetes

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Link zum Volltext

Verfügbarkeit prüfen

97-LB: Empagliflozin Improves Cardiopulmonary Function and VE/VCO2 in Patients with T2D and HFrEF

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Link zum Volltext

Verfügbarkeit prüfen

68-LB: Early Pharmacological Intervention (EPIC) to Preserve Beta-Cell Function in Prediabetes (PreDM)

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Link zum Volltext

Verfügbarkeit prüfen

98-LB: Effects of SGLT2 Inhibition on Skeletal Muscle Bioenergetics and Myocellular Lipids in Patients with T2D and HFrEF

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Link zum Volltext

Verfügbarkeit prüfen

Improving Outcomes of People With Diabetes Through Overcoming Therapeutic Inertia

Diabetes spectrum, 2020-02, Vol.33 (1), p.5-6

2020

Link zum Volltext

Verfügbarkeit prüfen

756-P: Bromocriptine-QR (BQR) Ameliorates Immunocyte Pro-Oxidative Stress/Proinflammatory (POS/PI) and ER Stress Phenotype in T2DM Subjects

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Link zum Volltext

Verfügbarkeit prüfen

Bromocriptine-QR Therapy Reduces Sympathetic Tone and Ameliorates a Pro-Oxidative/Pro-Inflammatory Phenotype in Peripheral Blood Mononuclear Cells and Plasma of Type 2 Diabetes Subjects

International journal of molecular sciences, 2022-08, Vol.23 (16), p.8851

2022

Link zum Volltext

Verfügbarkeit prüfen

1070-P: Bromocriptine-QR (BQR) Ameliorates a Pro-oxidative Stress/Proinflammatory (POS/PI) Monocyte Phenotype in Poorly Controlled T2DM Subjects

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Link zum Volltext

Verfügbarkeit prüfen

1136-P: Glucose Kinetics during Oral Glucose Challenge following Administration of Exenatide and Dapagliflozin Alone and in Combination in Type 2 Diabetes

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 119

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(107)
Mit Volltextzugriff
(105)

Publikationsform

Artikel
(119)

Sprache

Erscheinungsjahr

n.n

Thema

Diabetes
(64)
Humans
(53)
Life Sciences & Biomedicine
(47)
Science & Technology
(47)
Diabetes Mellitus
(45)
Diabetes Mellitus, Type 2 - Drug Therapy
(43)
Glucose
(38)
Insulin
(36)
Endocrinology & Metabolism
(34)
Hypoglycemic Agents - Therapeutic Use
(30)
Male
(26)
Female
(23)
Middle Aged
(23)
Insulin Resistance
(21)
Blood Glucose
(20)
Metformin
(19)
Blood Glucose - Metabolism
(17)
Glucagon
(16)
Research Design
(15)
Drug Therapy, Combination
(14)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Assessment of pancreatic β-cell function: review of methods and clinical applications

Therapeutic Manipulation of Myocardial Metabolism

Understanding the kidneys' role in blood glucose regulation

887-P: Renal Benefit of Dapagliflozin Therapy in Hyperfiltering Type 2 Diabetes Patients

124-OR: Effects of Dapagliflozin Therapy on Renal Hemodynamics in Type 2 Diabetes Patients

Examining the mechanisms of glucose regulation

Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists

A Special Thanks to Lyn Reynolds, Director of the ADA Editorial Office, as She Embarks on Her Retirement

A Special Thanks to Lyn Reynolds, Director of the ADA Editorial Office, as She Embarks on Her Retirement

857-P: Mechanisms of Dapagliflozin to Reduce Intraglomerular Pressure in Patients with Type 2 Diabetes

Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients

99-LB: Myocardial Blood Flow in Association with Baseline Ejection Fraction after Elevation in Plasma Ketones in Patients with T2DM and Heart Failure

Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy

Oh, What Times We Live In

Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors

644-P: Effect of PharmacologIC (EPIC) Therapy on Insulin Sensitivity and Beta-Cell Function in Prediabetes (PreDM)

175-OR: Effect of Hyperketonemia on Cardiac Efficiency in Patients with Heart Failure and Type 2 Diabetes

97-LB: Empagliflozin Improves Cardiopulmonary Function and VE/VCO2 in Patients with T2D and HFrEF

68-LB: Early Pharmacological Intervention (EPIC) to Preserve Beta-Cell Function in Prediabetes (PreDM)

98-LB: Effects of SGLT2 Inhibition on Skeletal Muscle Bioenergetics and Myocellular Lipids in Patients with T2D and HFrEF

Improving Outcomes of People With Diabetes Through Overcoming Therapeutic Inertia

756-P: Bromocriptine-QR (BQR) Ameliorates Immunocyte Pro-Oxidative Stress/Proinflammatory (POS/PI) and ER Stress Phenotype in T2DM Subjects

Bromocriptine-QR Therapy Reduces Sympathetic Tone and Ameliorates a Pro-Oxidative/Pro-Inflammatory Phenotype in Peripheral Blood Mononuclear Cells and Plasma of Type 2 Diabetes Subjects

1070-P: Bromocriptine-QR (BQR) Ameliorates a Pro-oxidative Stress/Proinflammatory (POS/PI) Monocyte Phenotype in Poorly Controlled T2DM Subjects

1136-P: Glucose Kinetics during Oral Glucose Challenge following Administration of Exenatide and Dapagliflozin Alone and in Combination in Type 2 Diabetes

Suchergebnisse filtern